Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FNCH Finch Therapeutics Group	$12.75 -1.9%	$13.26	$1.27 ▼ $15.85	$20.88M	1.21	2,149 shs	1,741 shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
ITOS iTeos Therapeutics	$10.21 -0.2%	$9.22	$4.80 ▼ $18.13	$391.54M	1.49	693,493 shs	536,023 shs
PHAR Pharming Group	$9.98 -0.3%	$10.53	$6.65 ▼ $12.61	$680.99M	0.02	6,105 shs	5,740 shs
PHVS Pharvaris	$19.83 +7.2%	$17.13	$11.51 ▼ $25.50	$967.37M	-2.82	70,815 shs	58,015 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FNCH Finch Therapeutics Group	-1.92%	-2.49%	-4.76%	+2.82%	+858.65%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
ITOS iTeos Therapeutics	-0.20%	+0.39%	+1.79%	+80.71%	-33.05%
PHAR Pharming Group	-0.35%	-3.90%	-15.47%	+23.91%	+17.22%
PHVS Pharvaris	+7.19%	+5.70%	+9.44%	+65.25%	+11.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FNCH Finch Therapeutics Group	1.1444 of 5 stars	0.0	3.0	0.0	0.0	2.9	1.7	0.6
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	3.3524 of 5 stars	4.1	2.0	0.0	0.0	2.0	3.3	0.6
PHAR Pharming Group	3.003 of 5 stars	3.5	5.0	0.0	0.0	2.6	0.0	0.6
PHVS Pharvaris	1.5407 of 5 stars	3.5	1.0	0.0	0.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
GRCL Gracell Biotechnologies	0.00	N/A	N/A	N/A
ITOS iTeos Therapeutics	2.14	Hold	$15.86	55.31% Upside
PHAR Pharming Group	3.00	Buy	$30.00	200.75% Upside
PHVS Pharvaris	3.00	Buy	$36.20	82.55% Upside

Current Analyst Ratings Breakdown

Latest PHVS, ITOS, FNCH, GRCL, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/14/2025	ITOS iTeos Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$47.00 ➝ $9.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
GRCL Gracell Biotechnologies	$60K	12,415.83	N/A	N/A	$2.95 per share	3.47
ITOS iTeos Therapeutics	$35M	11.16	N/A	N/A	$16.16 per share	0.63
PHAR Pharming Group	$320.71M	2.12	$0.07 per share	135.04	$3.25 per share	3.07
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
GRCL Gracell Biotechnologies	-$88.08M	-$1.05	N/A	N/A	N/A	N/A	-37.40%	-31.24%	N/A
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	332.50	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)

Latest PHVS, ITOS, FNCH, GRCL, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PHAR Pharming Group	-$0.15	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FNCH Finch Therapeutics Group	N/A	3.87	3.87
GRCL Gracell Biotechnologies	0.02	7.73	7.73
ITOS iTeos Therapeutics	N/A	14.13	14.13
PHAR Pharming Group	0.39	2.76	2.00
PHVS Pharvaris	N/A	11.10	11.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FNCH Finch Therapeutics Group	21.77%
GRCL Gracell Biotechnologies	N/A
ITOS iTeos Therapeutics	97.16%
PHAR Pharming Group	0.03%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
FNCH Finch Therapeutics Group	44.90%
GRCL Gracell Biotechnologies	28.00%
ITOS iTeos Therapeutics	12.50%
PHAR Pharming Group	2.07%
PHVS Pharvaris	11.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
GRCL Gracell Biotechnologies	314	72.68 million	52.33 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable

PHVS, ITOS, FNCH, GRCL, and PHAR Headlines

Recent News About These Companies

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

July 10 at 7:02 AM | globenewswire.com

Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) PT at $36.20

July 9 at 2:13 AM | americanbankingnews.com

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Buy" from Brokerages

July 6, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Shares Gap Up - What's Next?

July 3, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Trading Down 4.9% - What's Next?

June 27, 2025 | marketbeat.com

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

June 27, 2025 | globenewswire.com

Pharvaris N.V. (9EN.F) stock price, news, quote & history - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and Pharvaris (PHVS)

June 24, 2025 | theglobeandmail.com

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...

June 16, 2025 | gurufocus.com

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...

June 16, 2025 | gurufocus.com

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

June 16, 2025 | globenewswire.com

Pharvaris (NASDAQ:PHVS) Given Average Rating of "Buy" by Brokerages

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Pharvaris FY2026 Earnings

June 11, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS)

June 11, 2025 | marketbeat.com

Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials

June 10, 2025 | tipranks.com

Pharvaris Announces Annual Meeting of Shareholders

June 10, 2025 | globenewswire.com

Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials

June 5, 2025 | tipranks.com

Pharvaris reports promising results for deucrictibant in HAE

June 3, 2025 | investing.com

Pharvaris reports promising results for deucrictibant in HAE

June 3, 2025 | investing.com

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...

June 2, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, ITOS, FNCH, GRCL, and PHAR Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

$12.75 -0.25 (-1.92%)

As of 07/10/2025 01:49 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

iTeos Therapeutics NASDAQ:ITOS

$10.21 -0.02 (-0.20%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$10.22 +0.00 (+0.05%)

As of 07/10/2025 04:06 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Pharming Group NASDAQ:PHAR

$9.98 -0.04 (-0.35%)

Closing price 07/10/2025 03:51 PM Eastern

Extended Trading

$10.10 +0.13 (+1.30%)

As of 05:30 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Pharvaris NASDAQ:PHVS

$19.83 +1.33 (+7.19%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$19.96 +0.14 (+0.68%)

As of 07/10/2025 07:58 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time